xeljanz for alopecia areata - Yahoo Search Results

Ads
related to: xeljanz for alopecia areata
XELJANZ® (tofacitinib) - Safety & Side Effects

www.xeljanz.com
View Prescribing Info, Safety Info & Boxed Warning. Official Patient Site For Rx XELJANZ®. It’s Important To Talk With Your Doctor About How Your Current Treatment Plan Is Working.
Types: Co-Pay Savings Card, Clinical Trial Info, XelSource Support Program
XELJANZ® Co-Pay Savings
Learn About The Co-Pay Savings

Program & Eligibility Requirements

Doctor Finder Tool
Find A Healthcare Provider Near You

On The Rx XELJANZ® Patient Site

Connect With XelSource
Call XelSource To Learn About

Potential Savings For Rx XELJANZ®

Patients In Focus
Hear From Real Rx XELJANZ® Patients

To Learn About Their Experiences

Prescribing Info
See Full Prescribing Info And

Boxed Warning For Rx XELJANZ®

Patient Resources
Find Additional Patient

Resources For Rx XELJANZ®
SKYRIZI® (risankizumab-rzaa) - Another Treatment Option

skyrizi.com
Are You Thinking About A Treatment Plan Change? See If SKYRIZI® Is Right For You. View Real Results From Real Patients. Hear Real Patient Stories For SKYRIZI® Treatment.
SKYRIZI® Dosing Info
Register For More Info
Find a Doctor
SKYRIZI Results
SKYRIZI Resources

Search results

- Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata
  Zacks via Yahoo Finance· 2 years ago
  Eli Lilly LLY and partner Incyte INCY announced that the FDA has granted approval to their oral JAK...
- Nature's answer to JAK3 inhibition: Discovering five herbal and natural alternatives
  The Gainesville Sun via Yahoo News· 6 months ago
  JAK3 inhibitors have become a buzzword in pharmaceuticals, with significant implications for...
- My Top Value Stock to Buy In 2023
  Motley Fool· 1 year ago
  The past three years have been significant for pharma giant Pfizer (NYSE: PFE) and its shareholders. For instance, Pfizer's shares remain reasonably...
- Pfizer's (PFE) Q3 Loss Narrows, Sales Miss on COVID Slump
  Zacks via Yahoo Finance· 7 months ago
  Pfizer PFE reported third-quarter 2023 adjusted loss per share of 17 cents, which was narrower than...
- Pfizer (PFE) to Report Q2 Earnings: Here's What to Expect
  Zacks via Yahoo Finance· 10 months ago
  Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like...
- Pfizer's (PFE) Etrasimod Filings Receive Review Acceptance
  Zacks via Yahoo Finance· 1 year ago
  The regulatory filings seek approval for Pfizer's (PFE) etrasimod in UC indication. A final decision...
- Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
  Zacks via Yahoo Finance· 2 weeks ago
  Pfizer PFE reported first-quarter 2024 adjusted earnings per share of 82 cents, which comfortably...
- Here's Why Pfizer's High-Yield Dividend Could Be Even Safer Than You Might Think
  Motley Fool· 9 months ago
  Pfizer (NYSE: PFE) reported a 53% year-over-year decline in revenue in its latest quarter. There's...
- Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?
  Zacks via Yahoo Finance· 7 months ago
  Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter,...
- Pfizer (PFE) Q4 Earnings Top, Revenues Miss on COVID Sales Slump
  Zacks via Yahoo Finance· 4 months ago
  Pfizer PFE reported fourth-quarter 2023 adjusted earnings per share of 10 cents in contrast to the...